We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 924

Sandoz v Amgen: An update
  • Bristows LLP
  • USA
  • January 9 2018

In our most recent publication, the Bristows' Biotech Review (Page 3), we reported on the US Supreme Court decision which, at the time, was the latest


Anticipated Acts of Infringement May Establish Venue for Hatch-Waxman
  • McDermott Will & Emery
  • USA
  • October 31 2017

Addressing venue in the context of Hatch-Waxman litigation, the US District Court for the District of Delaware held that venue is proper in Delaware


专利权利用尽和制药业
  • Dilworth IP
  • USA
  • September 28 2017

5月30日最高法院在Impression Products, Inc. v. Lexmark International


Amgen Files Infringement Suit Against Mylan Over Neulasta Biosimilar
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • September 28 2017

Amgen has filed patent infringement claims against Mylan and its subsidiaries over Mylan’s proposed biosimilar version of Neulasta (pegfilgrastim


New Patent Infringement Cases Provide Guidance on Analyzing Venue in the Wake of TC Heartland
  • Greenberg Traurig LLP
  • USA
  • September 19 2017

On May 22, 2017, the Supreme Court issued a watershed decision in TC Heartland LLC v. Kraft Food Group Brands LLC, 137 S. Ct. 1514 (2017), analyzing


U.S. - What does the Impression Products v. Lexmark decision mean for drug companies? 5 takeaways
  • Hogan Lovells
  • USA
  • September 11 2017

Last May, the U.S. Supreme Court issued a highly-anticipated decision in Impression Products, Inc. v. Lexmark Int’l, Inc., reversing the Federal


At The Bench: 2017 Mid-Year Case Review
  • Harness, Dickey & Pierce, PLC
  • USA
  • September 7 2017

The Supreme Court held that all patent rights are exhausted upon the first sale of a Patented product, regardless of where the sale is made or whether


The legal and regulatory challenges of getting a biosimilar product to market
  • CMS Cameron McKenna Nabarro Olswang LLP
  • USA, European Union
  • August 30 2017

The global biosimilars market is expected to reach $10.9 billion by 2021, according to the Biosimilars Global Forecast


Third Circuit Holds No Sham Litigation or Unlawful Reverse Payment in Wellbutrin XL Litigation
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • August 25 2017

The Third Circuit recently affirmed the grant of summary judgment to GlaxoSmithKline (“GSK”) in the nearly 10-year-old Wellbutrin XL Antitrust


The Federal Circuit Weighs in on the Doctrine of Equivalents for Chemical Inventions
  • K&L Gates
  • USA
  • July 31 2017

In Mylan Institutional LLC v. Aurobindo Pharma Ltd., he Federal Circuit affirmed the district court granting a preliminary injunction based on